Jazz Pharmaceuticals (JAZZ) Fundamentals Remain Strong, PT Raised - UBS

August 7, 2013 12:50 PM

UBS raised its price target on Buy-rated Jazz Pharmaceuticals (NASDAQ: JAZZ) from $80 to $87, saying while Q2 missed, fundamentals ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found